Johnson & Johnson
Pharmaceuticals New Brunswick, New Jersey 133,900 employees
jnj.com Johnson & Johnson is a multinational corporation that develops medical devices, pharmaceuticals, and consumer health products.
48
Risk Score
40,706
Total Laid Off
16
Layoff Rounds
41%
Layoff Prediction
Positive
News Sentiment
—
Debt/Equity
—
Exec Turnover (12m)
None
Regulatory Scrutiny
Leading
Innovation
About
Johnson & Johnson is a multinational corporation that develops medical devices, pharmaceuticals, and consumer health products.
Company Size
5000+
~133,900 employees
Stock Performance
stable
Leadership
- Joaquin Duato
- Joseph Wolk
Products & Services
Pharmaceuticals
Medical Devices
Consumer Health
Innovation Insights
Innovation Score
90/100
R&D Activity
High
Competitive Position
Leading in oncology and cardiovascular MedTech sectors. ([business.ricentral.com](https://business.ricentral.com/ricentral/article/finterra-2026-1-19-the-new-era-of-johnson-and-johnson-a-2026-deep-dive-research-feature?utm_source=openai))
- • Approval of CAPLYTA for major depressive disorder. ([investor.jnj.com](https://investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q4-and-Full-Year-2025-results/default.aspx?utm_source=openai))
- • Submission of OTTAVA Robotic Surgical System for FDA De Novo classification. ([business.ricentral.com](https://business.ricentral.com/ricentral/article/finterra-2026-1-19-the-new-era-of-johnson-and-johnson-a-2026-deep-dive-research-feature?utm_source=openai))
Regulatory & Legal Warnings
Legal
High
2025Ongoing litigation related to talc products. ([time.com](https://time.com/7212011/joaquin-duato-johnson-and-johnson-interview/?utm_source=openai))
Impact: Potential financial liabilities and reputational damage.
Regulatory
Medium
2025Anticipated $400 million in tariff-related costs, primarily affecting the medical technology division. ([apnews.com](https://apnews.com/article/103d0074599788cf6f3ceee93269c3d2?utm_source=openai))
Impact: Increased operational expenses.
Layoff Timeline (employees affected)
Most Affected Departments
July 27, 2026
Divisional restructuring following consumer health split
400
employees
July 5, 2026
Economic
120
employees
May 31, 2026
Corporate restructuring
86
employees
December 15, 2025
Restructuring and focus on core businesses
2,500
employees
December 10, 2025
Post-pandemic demand decline
3,000
employees
November 20, 2024
Post-pandemic demand decline
1,500
employees
November 1, 2024
MedTech restructuring
MedTechOperations
2,300
employees
December 25, 2022
Restructuring and cost-cutting measures
500
employees
November 17, 2022
Restructuring and cost-cutting measures
5,000
employees
June 15, 2022
Restructuring
5,000
employees
March 30, 2022
Restructuring and cost-cutting measures
300
employees
March 16, 2022
Restructuring and cost-cutting measures
11,000
employees
March 15, 2022
Restructuring and cost-cutting measures
500
employees
March 2, 2022
Restructuring manufacturing division
1,500
employees
March 1, 2022
Restructuring and cost-cutting measures
1,000
employees
February 25, 2022
Cost-cutting measures
6,000
employees